Azenta, Inc. (AZTA) 股票分析

公司概述

Azenta, Inc. operates within the healthcare sector, specifically focusing on the medical instruments and supplies industry, where it delivers comprehensive biological and chemical compound sample exploration and management solutions to the life sciences industry across the United States, China, the United Kingdom, Europe, the Asia Pacific region, and internationally. The company's operational scope is structured through two primary segments: Sample Management Solutions and Multiomics, which collectively serve global research and development needs for pharmaceutical and biotechnology entities. As of the latest data, Azenta holds a market capitalization of $1.04B and reported annual revenue (TTM) of $595.03M, supported by an workforce of 3000 employees. These valuation and revenue figures position Azenta as a mid-to-large-cap entity within the specialized life sciences support market, indicating a substantial operational footprint and significant resource allocation for its global sample management infrastructure.

财务健康

Azenta reported a total revenue of $595.03M over the trailing twelve months, with a net income of $26.34M and an EBITDA of $37.33M, revealing a distinct gap between gross earnings and bottom-line profit that highlights the significant impact of operating expenses and taxes on the final financial result. The company generated $108.52M in free cash flow, a figure that underscores strong financial flexibility despite operating margin pressures, allowing for potential capital expenditures or strategic acquisitions without immediate external financing. The gross margin stands at 44.6%, reflecting the high-value nature of its specialized compound management services, while the operating margin is negative at -4.1% and the profit margin is negative at -10.1%, indicating that the company is currently prioritizing expansion or investing heavily in operational scaling over immediate profitability. In terms of leverage, the company holds $409.66M in cash against $54.46M in debt, resulting in a debt-to-equity ratio of 3.18, which suggests a highly leveraged balance sheet structure where equity is the primary funding source relative to liabilities. The current ratio of 2.92 demonstrates robust short-term liquidity, confirming the firm's ability to cover its current liabilities with current assets more than twice over. Furthermore, the return on equity is 1.5% and the return on assets is -0.6%, metrics that collectively indicate management is currently generating minimal returns on shareholder capital and a slight loss on the total asset base, likely due to the negative profit margin environment.

估值评估

The trailing P/E ratio is 39.07, while the forward P/E is significantly lower at 21.05, implying that the market expects earnings to increase substantially in the future to justify the current stock price, although the gap suggests high current expectations or a correction in current earnings quality. The price-to-book ratio is 0.61, indicating that the company's market valuation is trading below its book value, which often signals a market discount relative to the assets recorded on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 1.75 and an EV/EBITDA of 18.45 provide additional context, suggesting that despite the low P/B, the market is willing to pay a premium relative to sales and earnings before interest, taxes, depreciation, and amortization. The stock's 52-week high is $41.73 and the 52-week low is $19.87, establishing a trading range of approximately $21.86, which defines the volatility band within which the security has fluctuated over the past year. The beta value of 1.47 indicates that the stock is 47% more volatile than the broader market, meaning it experiences amplified price swings during periods of market stress or growth, presenting higher risk characteristics for conservative portfolios.

Growth & Income

Azenta's revenue growth year-over-year is 0.8%, while earnings growth is listed as N/A, suggesting that revenue expansion is the primary driver of activity rather than immediate earnings acceleration, as the company navigates its transition or investment phase. Since the company does not currently pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, all earnings are effectively reinvested back into the business to fund operations, R&D, or market expansion rather than being distributed to shareholders. The absence of a dividend payout implies that the company's growth strategy relies on internal capital generation and operational scaling rather than income distribution, which is typical for firms with negative or low profit margins seeking to stabilize operations. Overall, Azenta presents a growth-oriented profile with minimal current income generation, characterized by low revenue growth, negative profitability, and a capital-light approach to shareholder returns through reinvestment.